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ABSTRACT
The control of Mycoplasma hyorhinis infection relies mainly on antimicrobial therapy. However, the
antibiotic susceptibility testing of the bacteria is usually not performed before applying the treatment,
and thus therapeutic failures are not uncommon. In the case of M. hyorhinis, several antibiotic-resis-
tance-related single nucleotide polymorphisms (SNPs) are known but assays for their detection have not
been described yet. The aims of the present study were to investigate macrolide- and lincomycin-
resistance-related SNPs in Hungarian M. hyorhinis isolates and to develop mismatch amplification
mutation assays (MAMA) to detect the identified resistance markers. Minimal inhibitory concentra-
tions (MIC) of different drugs and whole genome sequences of 37 M. hyorhinis isolates were used to
find the resistance-related mutations. One MAMA assay was designed to detect the mutation of the 23S
rRNA gene at nucleotide position 2058 (Escherichia coli numbering). For further evaluation, the assay
was challenged with 17 additional isolates with available MIC data and 15 DNA samples from clinical
specimens. The genotypes of the samples were in line with the MIC test results. The developed assay
supports the practice of targeted antibiotic usage; hence it may indirectly reduce some bacterial resis-
tance-related public health concerns.
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INTRODUCTION
Mycoplasma hyorhinis is a facultative pathogenic Mycoplasma species causing polyserositis
and arthritis in weaners and finishers from 3 to 10 weeks of age (Rovira et al., 2010). It can
also induce more severe lung lesions in animals infected with Mycoplasma hyopneumoniae or
porcine reproductive and respiratory syndrome virus (Lee et al., 2016; Luehrs et al., 2017).
The infection results in significant economic losses worldwide (Hansen et al., 2010). A
vaccine is available against M. hyorhinis infection (Ingelvac MycoMAXTM, Boehringer
Ingelheim Animal Health USA Inc., Duluth, USA) in the United States, but the reduction of
incidence still relies mainly on prevention by providing optimal housing conditions and the
protection against other, viral pathogens (Palzer et al., 2015). A proper antibiotic treatment
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can decrease the severity of clinical signs of the infection
and, thus, reduce the economic losses. The in vitro antibiotic
susceptibility of Mycoplasma species is tested by the broth or
agar microdilution method. Both methods are labour-
intensive and time-consuming techniques which require the
prior isolation of the pathogen. Therefore, antibiotic sus-
ceptibility testing prior to treatment is often not possible and
antimicrobials are chosen empirically, which can lead to the
development of antimicrobial resistance (Kobayashi et al.,
2005). Further difficulties are the lack of standard break-
points and international standards which complicate the
interpretation and comparison of the results (Hannan, 2000;
Kreizinger et al., 2017; Bek}o et al., 2019).
Macrolide and lincosamide antimicrobials inhibit the
bacterial protein synthesis by binding to the 50S subunit of
the ribosome. Resistances to both of these groups are often
linked because of the overlap of the binding sites at the 23S
rRNA of the 50S subunit (Py€or€al€a et al., 2014). Mycoplasma
hyorhinis is intrinsically resistant to 14-membered macro-
lides (Ter Laak et al., 1991; Wu et al., 2000) and a decreased
susceptibility to 15- and 16-membered macrolides has also
been reported (Kobayashi et al., 1996, 2005; Jang et al., 2016;
Bek}o et al., 2019; Rosales et al., 2020). In vitro selected
resistant mutants and Japanese field isolates have been
investigated for resistance-related point mutations (SNPs) in
the 23S rRNA gene and the L4, L22 protein genes of the 50S
ribosome by Kobayashi et al. (2005). A point mutation
A2059G (according to Escherichia coli numbering) at the V
domain of the 23S rRNA was found in in vitro mutants and
field isolates as well. In addition, point mutations between
nucleotide positions 2058 and 2062 (E. coli numbering) were
connected to macrolide and lincosamide resistance in several
Mycoplasma species (Sulyok et al., 2017; Chernov et al.,
2018; Gautier-Bouchardon, 2018; Bek}o et al., 2020a; Felde
et al., 2020).
The aim of the present study was to investigate Hun-
garian M. hyorhinis isolates for macrolide and lincomycin
resistance-related SNPs and to develop rapid and cost-
effective molecular biological assays for their detection.
MATERIALS AND METHODS
Mycoplasma hyorhinis strains, clinical samples and
susceptibility testing
In this study, 55 M. hyorhinis isolates from previous studies
(Bek}o et al., 2019; F€oldi et al., 2020) or collected in 2019–
2020 and the type strain NCTC 10130 (GenBank Accession
number: LS991950.1) were used. DNA extracted from the
original clinical specimens of 15 clinical isolates was also
examined (Supplementary Table 1). All samples originated
from Hungary except for two isolates, MycSu60 and
MycSu213 which originated from Slovakia. Ethical approval
was not required for the study as the samples were taken
either during routine diagnostic examinations with the
consent of the owners or in slaughterhouses. The isolates
collected in 2019–2020 were cultured as described before
(Bek}o et al., 2019). DNA extraction from the clinical spec-
imens and the field isolates was performed using the
QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA, USA)
according to the manufacturer’s instructions for Gram-
negative bacteria. All isolates were identified by polymerase
chain reaction (PCR) targeting the p37 gene of M. hyorhinis
(Assunç~ao et al., 2005). The presence of other Mycoplasma
species was excluded by a universalMycoplasma PCR system
targeting the 16S/23S rRNA intergenic spacer region in
Mollicutes (Lauerman et al., 1995) followed by sequencing
on an ABI Prism 3100 automated DNA sequencer (Applied
Biosystems, Foster City, USA), then sequence analysis and
BLASTN search (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
The DNA samples were tested for the presence of M.
hyopneumoniae, Mycoplasma hyosynoviae and Mycoplasma
flocculare as well by a species-specific PCR according to
Assunç~ao et al. (2005). Detailed information about the M.
hyorhinis isolates used in the study can be found in Sup-
plementary Table 1.
The antibiotic susceptibility of 38 isolates to macrolides
(tylosin, tilmicosin, tylvalosin, tulathromycin, gami-
thromycin) and lincomycin has been previously determined
by the broth microdilution method (Bek}o et al., 2019) ac-
cording to Hannan (2000). The susceptibility of further 17
isolates to at least one macrolide and in some cases to
lincomycin was determined in this study as described before
(Bek}o et al., 2019). Briefly, 104 colour changing units/mL
(CCU/mL) of the isolates were tested in duplicates. The
antibiotics originated from VETRANAL (Sigma-Aldrich
Chemie GmbH, Taufkirchen, Germany) except for tylvalo-
sin (Aivlosin), which was purchased from ECO Animal
Health Ltd. (London, UK). Stock solutions of 1mg/mL were
prepared in sterile distilled water, and stored at –70 8C, ac-
cording to the recommendations of Hannan (2000). For
each test, freshly prepared twofold dilutions of the antibi-
otics were made in the concentration range of 0.25–64 mg/
mL. The M. hyorhinis type strain (NCTC 10130) was
included in each plate to confirm the validity of the results.
The initial minimal inhibitory concentration (MIC) of each
strain was defined as the lowest concentration of the anti-
biotic that completely inhibited the growth at the time of
colour change in the growth control. Since there are no
official breakpoints available for the antibiotic susceptibility
testing of M. hyorhinis, previously published breakpoints for
M. hyopneumoniae or other porcine respiratory pathogens
were used (Hannan et al., 1997; Felde et al., 2020; Vilaro
et al., 2020). MIC values ≥4 mg/mL of tylosin, tylvalosin,
gamithromycin and lincomycin were considered high
(Hannan et al., 1997; Felde et al., 2020), while for tilmicosin
and tulathromycin higher breakpoints were suggested, thus
MIC values ≥16 mg/mL were considered high (Vilaro et al.,
2020).
Development of the assay
Single nucleotide polymorphisms associated with high (ge-
notype H) or low (genotype L) MIC values were identified
by analysing the whole genome sequences of 37M. hyorhinis
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field isolates and the type strain (NCTC 10130). The
sequencing was performed as described before (F€oldi et al.,
2020).
The 23S rRNA and 50S ribosomal protein L4 and L22
coding genes were previously connected to macrolide and
lincomycin resistance in Mycoplasma species (Kobayashi
et al., 2005; Sulyok et al., 2017; Bek}o et al., 2020a; Felde et al.,
2020). These genes were aligned and analysed in Geneious
Prime software version 2019.2.1 (Kearse et al., 2012) to
detect SNPs. In the protein-coding genes only SNPs result-
ing in amino acid change were analysed, but in the 23S
rRNA gene all SNPs were investigated. The numbering of
nucleotide position according to E. coli strain K-12 substrain
MG1655 (GenBank accession number: NC_000913) is
indicated in parentheses throughout the text to enable the
comparison of our results with data of the literature.
Nevertheless, nucleotide positions are discussed in the text
based on the numbering of individual genes of the M.
hyorhinis type strain (NCTC 10130) in order to avoid mis-
understandings due to gaps in the alignment. To identify
potentially resistance-related SNPs, the correlation between
the MIC values and the occurrence of mutations were ana-
lysed. Mutations were considered resistance-related when
they occurred more frequently with increasing MIC values
or exclusively in isolates with high MIC values.
To detect the resistance-related SNPs, mismatch ampli-
fication mutation assays (MAMA) were designed. In brief,
MAMA is a molecular biological tool to discriminate SNP in
bacteria. The assay is based on competing allele-specific
primers, which are SNP specific at the 30 end and contain a
single destabilising mismatch at the antepenultimate posi-
tion of the 30 end to enhance the discriminatory power. One
of the allele-specific primers is marked with an additional
15- to 20-bp-long GC clamp that increases the melting
temperature and the size of the amplicon as well. The
temperature shift is detected on a real-time PCR platform in
the presence of an intercalating fluorescent DNA dye (melt-
MAMA) and the size difference is revealed in agarose gel
electrophoresis (agarose-MAMA) (Birdsell et al., 2012;
Sulyok et al., 2018; Bek}o et al., 2020b; Felde et al., 2020).
Primers were designed based on the whole genome se-
quences of M. hyorhinis field isolates and the type strain
(NCTC 10130) in the Geneious Prime software version
2019.2.1 (Kearse et al., 2012). Melting temperatures and
suitability were calculated using the NetPrimer software
(Premier Biosoft International, Palo Alto, CA, USA) and the
specificity of the primers was checked with BLASTN
(https://blast.ncbi.nlm.nih.gov/Blast.cgi).
The agarose-MAMA PCR mixture consisted of 5 mL 53
Green GoTaq Flexi buffer (Promega Inc., Madison, WI,
USA), 2.5mL MgCl2 (25mM; Promega), 0.5mL dNTP
(10mM; Qiagen), 0.2 mL GoTaq Polymerase (5 U/mL,
Promega), 1 mL DNA template and primers according to
Table 1 with a total volume of 25 mL. The PCR was per-
formed on a Bio-Rad C1000 TouchTM Thermal Cycler (Bio-
Rad Laboratories Inc., Hercules, CA, USA). The thermocy-
cling parameters were 95 8C for 5min followed by 35 cycles
of 95 8C for 30 s, 60 8C for 30 s and 72 8C for 30 s. The final
elongation step was performed at 72 8C for 5min. After
amplification, 5mL of each reaction mixture were submitted
to electrophoresis in 3% agarose gel (MetaPhor Agarose,
Lonza Inc., Rockland, ME, USA) using a 20-bp DNA ladder
(O’RangeRuler 20 bp, Thermo Fisher Scientific, Waltham,
USA) as a molecular weight marker. The amplified PCR
products were visualised with ECO Safe Nucleic Acid
Staining Solution (Pacific Image Electronics Inc., Torrance,
CA, USA), under UV light. The melt-MAMA PCR mixture
contained 4.5mL 2x HSTaq Mix (PCR Biosystems Ltd.,
London, UK), 0.5mL EvaGreen (20X, Biotium Inc., Hay-
ward, USA), 1 mL target DNA and primers according to
Table 1 in a final volume of 10 mL. The thermocycling pa-
rameters were 95 8C for 1min, followed by 35 cycles of 95 8C
for 15 s, 55 8C for 15 s and 72 8C for 5 s. The PCR products
were subjected to melt analysis using a dissociation protocol
comprising 95 8C for 15 s, followed by 0.3 8C incremental
temperature ramping from 55 8C to 95 8C. The real-time
PCRs were performed using Bio-Rad C1000 TouchTM
Thermal Cycler, CFX96TM Real-Time System (Bio-Rad
Laboratories Inc.). The EvaGreen fluorescence intensity was
measured at 525 nm at each ramp interval and plotted
against temperature.
Validation of the assay
In order to validate the developed assays, PCRs on 37 field
isolates with already established MIC values (Bek}o et al.,
2019; F€oldi et al., 2020) were performed. The resulting ge-
notypes (genotypes H and L) were compared with the
examined gene sequence.
In order to test the sensitivity of the developed assays,
tenfold dilutions of each genotype (M. hyorhinis type strain
(NCTC 10130) for genotype L and MycSu24 for genotype
Table 1. Primer sequences, volumes per reaction and results of the designed mismatch amplification mutation assay
Primer













23S-L TTACCCGCATCAAGACtAA 1.6 4 L 119 78.3–78.9
23S-H gggcgggcgggcgggcgggcTTACCCGCATCAAGACaAg 0.4 1 H 139 81.3–82.2
23S-C TCCACTAGAACTAGCGTCCC 0.4 1
a The GC-clamp, the targeted point mutation and the destabilising point mutation are in lower case; b Primer concentration: 10 pmol/mL.
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H) were used in the range of 108–100 copy number/mL. The
template copy number was calculated with the help of an
online tool (Staroscik, 2004) by measuring the concentration
of the DNA of pure M. hyorhinis culture by Nanodrop
(2000) Spectrophotometer (Thermo Fisher Scientific). The
lowest DNA concentrations detectable with agarose gel
electrophoresis or yielding melting temperature specific for
the genotype were considered the detection limit of the as-
says. The specificity was tested by including M. hyopneu-
moniae, M. hyosynoviae and M. flocculare in the analyses.
For further evaluation, an additional set of 17 strains was
tested and the assay was also challenged with 15 DNA
samples from clinical specimens. The genotypes resulting
from the DNAs of the clinical specimens were compared to
the genotypes of the isolates derived from these samples. The
tests were considered to give false results in those cases,
when the resulting genotype was not in line with the tested
MIC data. For the clinical specimens the tests were
considered to give false results when the resulting genotype
was not in line with the genotype of the isolate derived from
the sample.
RESULTS
After aligning the corresponding genes (23S rRNA and L4,
L22 50S ribosomal protein genes) of the M. hyorhinis type
strain (NCTC 10130) and the 37 Hungarian field isolates,
only one SNP, at nucleotide position A2066G (A2058G ac-
cording to E. coli numbering), in the 23S rRNA gene
(GenBank accession number: MW498281–MW498317), was
found to be related to macrolide and lincomycin resistance.
The primer sequences, fragment lengths and melting tem-
peratures of the developed MAMA, specific for the SNP, are
listed in Table 1. The developed assay successfully
distinguished genotypes H and L (Fig. 1) in the 55 clinical
isolates, the type strain (NCTC 10130) and the 15 DNA
samples from the clinical materials. The sensitivity of the
assay was 103 copy numbers/reaction for both genotypes in
the melt and the agarose assay as well. No cross reactions
were detected in the agarose-MAMA; however, M. flocculare
showed a genotype L specific melting temperature profile in
the melt-MAMA.
In the case of the clinical isolates, both the agarose- and
the melt-MAMA gave the same results. No false reactions
were detected for tylosin, tulathromycin and lincomycin.
False results were detected in one case for gamithromycin
(MycSu128) and tilmicosin (MycSu94) and in two cases for
tylvalosin (MycSu141, MycSu161). In MycSu128, MycSu141
and MycSu161, genotype H was detected; the isolates
showed elevated MIC values against five of the examined
antimicrobials, but were susceptible to the remaining one.
While MycSu94 was inhibited at an elevated MIC value of
tilmicosin, the isolate was susceptible to all the other
examined antimicrobials and presented genotype L in the
assays (Supplementary Table 1).
For the clinical specimens, the test of one DNA sample
(Su21) showed a mixed genotype by the agarose-MAMA,
while genotype H was determined in the corresponding
clinical isolate (MycSu101). The microdilution test showed
elevated MIC values of the tested antibiotics against of
MycSu101. At position 2066 in the whole genome sequence
of this isolate, a guanine nucleotide was found, and in line
with that, the assays of the pure culture resulted in genotype
H. The test of the clinical specimen Su21, however, resulted
in genotype L in the case of the melt-MAMA and double
amplicons in the size of both genotypes appeared by the
agarose-MAMA.
DISCUSSION
The control of M. hyorhinis infections depends mainly on
the use of antimicrobial agents. However, a targeted anti-
biotic treatment is usually inaccessible. Elevated MICs of
macrolides or lincomycin to M. hyorhinis isolates have been
reported from Japan, Korea, Hungary, Spain, Italy and
Portugal since 1996 (Kobayashi et al., 1996, 2005; Jang et al.,
2016; Bek}o et al., 2019; Rosales et al., 2020), and point
mutations associated with elevated MIC values were
described by Kobayashi et al. (2005). In the present study,
among Hungarian M. hyorhinis field isolates a transversion
substitution in the previously examined region, at position
2066 (2058 E. coli numbering) of the 23S rRNA was found,
an adenine was replaced by a guanine in the isolates with
elevated MIC values. A mismatch amplification mutation
assay was designed to detect this SNP in M. hyorhinis. The
developed MAMA is suitable to detect the SNP in agarose
gel based on template size differences, and in real-time PCR
based on template melting temperature differences. All iso-
lates showed uniformly high or low MIC results for all
examined macrolides and lincomycin in the broth micro-
dilution tests except for four (MycSu94, MycSu128,
Fig. 1. Determination of macrolide and lincomycin susceptibility by
the developed MAMA assay. Melting temperatures of the ampli-
cons for genotype L (Mycoplasma hyorhinis type strain NCTC
10130, blue line, Tm 78.6 8C) and genotype H (MycSu24, green line,
Tm 81.6 8C) were unique. The negative control (black line) was not
amplified. X axis: melting temperature (8C), Y axis: negative value
of the change in relative fluorescence units (RFU) over the change
in temperature
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MycSu141, MycSu161) where the MIC of one antibiotic
differed (Supplementary Table 1, highlighted with orange).
Consequently, the results of the developed MAMA corre-
sponded to the MIC values of the majority of the antibiotics
in these samples. In the case of MycSu94 we assume that an
evolving resistance is indicated by the elevated MIC value of
tilmicosin, which did not show up in a nucleotide change at
the examined position. Other SNPs or resistance mecha-
nisms can induce the elevated MIC value, but neither can be
determined based on one isolate. Against MycSu128,
MycSu141 and MycSu161, we would not advise the use of
macrolides, because besides the susceptibility to one of the
examined macrolides, highly elevated MIC values (≥64 mg/
mL) were observed for the majority of the antimicrobials.
Therefore, we believe that the result of the assay (genotype
H) supports the proper antibiotic treatment.
The assay is suitable for the examination of field isolates
and DNA extracted directly from clinical specimens. In one
case the detected genotype of the clinical specimen (in Su21
both genotypes were observed with the agarose-MAMA)
differed from the genotype of the isolate that derived from it
(in MycSu101 only genotype H was present). This can be
explained by the filter cloning step of the isolation: in vitro
testing and sequencing were made from the same one-col-
ony broth, but based on our observation, in the clinical
specimen probably more populations with different antibi-
otic susceptibility profiles were present.
In order to avoid the misinterpretation of the results due
to the presence of M. flocculare in the melt-MAMA, we
advise to submit the samples to a species-specific PCR first,
and in the presence of M. flocculare only the agarose-
MAMA is recommended. Clinical specimens with low spe-
cific DNA concentration (below 103 copy numbers/reaction)
may show false negative results, therefore in these cases
isolation prior to the test is suggested.
The developed assay is convenient, cost-effective and
provides data on the susceptibility of M. hyorhinis to criti-
cally important antimicrobials in a significantly shorter time
than the conventional MIC tests. The presented MAMA can
be performed directly on the clinical specimens using stan-
dard laboratory equipment and methods, therefore it is
suitable for routine diagnostic purposes.
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